PPARGC1A and metabolic dysfunction-associated steatotic liver disease: Collectively, these data establish a protective role for PRMT1 in NAFLD, whereby its methyltransferase activity activates the HNF‐4α/PGC‐1α pathway to enhance fatty acid oxidation and mitigate steatosis.